BioGenerator

IN10T Inc. is a digital agriculture company based in Chesterfield, Missouri, founded in 2016. The company specializes in designing and developing an internet-based platform for agronomic field research and data feeds. IN10T focuses on addressing farmer adoption challenges by providing customized digital and data science solutions tailored to the needs of agricultural stakeholders and investors. In addition to its platform, IN10T offers agricultural field data analysis and farm field testing services, enabling clients to make informed decisions based on comprehensive field data.

Geneoscopy develops non-invasive diagnostics using stool-derived eukaryotic RNA to prevent, detect, and guide treatment for gastrointestinal diseases. Its platform technology enables early-stage detection of colorectal cancer neoplasms and improves screening compliance.

SentiAR is a digital health software company developing a 3D augmented reality holographic platform that provides real-time visualization of a patient’s anatomy and catheter location during interventional procedures. Spun out from Washington University, it uses real-time mapping data and imaging from CT/MRI to render holographic views over the patient in the catheterization laboratory, with clinician-controlled visualization. The platform aims to improve precision and safety in procedures addressing cardiac arrhythmias. The company focuses on delivering an immersive visualization solution for interventional cardiology and related specialties.

Cadre Bioscience, LLC, founded in 2019 and based in Saint Louis, Missouri, is engaged in the development of therapeutics aimed at addressing various human diseases. The company focuses on accelerating the progression of early-stage therapeutic assets through a structured approach that emphasizes de-risking and development processes. Cadre Bioscience seeks to raise capital and attract skilled management to support its initiatives, facilitating the commercialization of innovative therapies for market access and patient benefit.

Healthy Bytes, Inc. is a healthcare company that specializes in personalized nutritional counseling through its innovative platform. Founded in 2014 and headquartered in Saint Louis, Missouri, with an additional office in New York, Healthy Bytes connects registered dietitians with employers to provide nutritional support for employees dealing with health issues such as obesity, diabetes, high blood pressure, and cardiovascular diseases. The platform facilitates private consultations, allowing users to book appointments with registered dietitians online. By utilizing their existing medical benefits, employees can access nutritional counseling at no additional cost, empowering them to lead healthier lifestyles. The company's approach enables dietitians to gain insight into their clients' eating habits, fostering more effective and tailored guidance.

Plastomics is a biotechnology company focused on chloroplast genetic engineering to enhance crop yields and nutritional quality. Its technology platform enables precise insertion of beneficial traits into chloroplasts, reducing cross-pollination and shortening breeding timelines. The company employs gene stacking and rapid breeding approaches to develop biotech crops with a broader set of traits, addressing industry challenges in seed development. Plastomics' approach is applicable across multiple crops and trait areas, supporting commercial trait expression while aiming to lower production costs. Founded in 2016 and headquartered in Saint Louis, Missouri.

Founded in 2016, Aggio develops cloud-based sales applications tailored for the agriculture industry. Its platform harmonizes multiple data sources, providing actionable insights for marketing and sales teams to engage customers and channel partners effectively.

Arch Innotek, LLC is a biotechnology company based in St. Louis, Missouri, that specializes in engineering microorganisms to produce natural ingredients beneficial for human and animal health. Founded in 2013, the company focuses on developing high-value molecules for various industries, including food, feed, pharmaceuticals, and cosmetics. Arch Innotek employs innovative fermentation processes, utilizing yeast to create natural carotenoid antioxidants and other sustainable ingredients. The company also offers services such as high-performance liquid chromatography (HPLC) analysis, liquid chromatography-mass spectrometry (LC-MS) analysis, protein purification, and molecular cloning, supporting its mission to provide healthier and affordable natural alternatives for consumers.

Canopy Biosciences, founded in 2016 and headquartered in St. Louis, Missouri, is a biotechnology company specializing in research tools for genetic engineering, molecular biology, and personalized medicine. The company offers a comprehensive range of products and services designed to facilitate gene editing, gene expression analysis, and bioprocessing. One of its key technologies, TUNR, targets translation elongation by inserting polyA tracks into specific coding regions of the genome, effectively reducing mRNA levels and suppressing protein expression. This innovative approach supports biomedical researchers at universities, research institutions, and within the biotechnology and pharmaceutical sectors, accelerating scientific discovery and enhancing the field of genetic engineering. Canopy Biosciences operates as a subsidiary of Bruker Corporation.

Kypha Inc. is a life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, the company offers the COMP ACT System, which enhances the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. Through its innovative platform, Kypha provides rapid and accurate assessments of inflammation levels, enabling healthcare professionals to make timely and informed clinical decisions. The company's approach facilitates testing across diverse settings, from home health care to clinical laboratories, ultimately aiming to improve patient outcomes by optimizing treatment strategies based on real-time immune insights. Since its incorporation in 2009, Kypha has attracted significant funding and built a strong network of scientific and clinical expertise to support its mission.

Atomation develops an IoT platform that connects existing devices, machines, and sensors to the internet. Its solutions enable businesses in sectors such as agriculture, medical, industrial, and logistics to gather data, draw insights, and make real-time decisions.

Plastomics is a biotechnology company focused on chloroplast genetic engineering to enhance crop yields and nutritional quality. Its technology platform enables precise insertion of beneficial traits into chloroplasts, reducing cross-pollination and shortening breeding timelines. The company employs gene stacking and rapid breeding approaches to develop biotech crops with a broader set of traits, addressing industry challenges in seed development. Plastomics' approach is applicable across multiple crops and trait areas, supporting commercial trait expression while aiming to lower production costs. Founded in 2016 and headquartered in Saint Louis, Missouri.

SentiAR is a digital health software company developing a 3D augmented reality holographic platform that provides real-time visualization of a patient’s anatomy and catheter location during interventional procedures. Spun out from Washington University, it uses real-time mapping data and imaging from CT/MRI to render holographic views over the patient in the catheterization laboratory, with clinician-controlled visualization. The platform aims to improve precision and safety in procedures addressing cardiac arrhythmias. The company focuses on delivering an immersive visualization solution for interventional cardiology and related specialties.

CoverCress Inc. specializes in developing and commercializing field pennycress as a sustainable oilseed crop for industrial oils and livestock feed. Founded in 2013, the company is headquartered in Saint Louis, Missouri.

MedAware Solutions, Inc. is a healthcare technology company based in St. Louis, Missouri, founded in 2014. It specializes in providing a comprehensive platform that facilitates communication and coordination among healthcare teams, including providers, payers, patients, and their families. The company's flagship product, mViva, serves as an all-in-one care coordination tool that allows multi-disciplinary teams to engage with patients throughout the continuum of care. This secure, HIPAA-compliant platform enables users to capture and share data efficiently, fostering collaboration and enhancing patient outcomes. By empowering individuals to participate in real-time conversations and access connected care, MedAware Solutions aims to optimize clinical resources and reduce healthcare costs.

MedSocket is a company that specializes in clinical decision support systems aimed at enhancing the efficiency and quality of patient care. It offers two patented technologies: the 1-Click Decision Support (1-CDS) system and a medical search engine called 1-Search. Designed by clinicians for clinicians, these tools provide rapid access to evidence-based information at the point of care, addressing the urgent information needs of healthcare providers. Both technologies have been successfully piloted at the University of Missouri Health System, demonstrating their potential to improve healthcare decisions, reduce errors, and ultimately enhance patient outcomes. MedSocket was founded by Dr. Karl Kochendorfer, who recognized the challenges healthcare providers faced in accessing timely information, and was later joined by Matt Botkin and Jayne Williams to bring together expertise in business and information science. The company aims to alleviate the burden on clinicians by streamlining information retrieval and decision-making processes in healthcare settings.

Euclises Pharmaceuticals, Inc. is a biopharmaceutical company focused on researching, developing, and commercializing innovative medicines for inflammation and oncology. Founded in 2011 and headquartered in Saint Louis, Missouri, the company aims to create novel pain and cancer treatments that demonstrate superior safety profiles compared to existing medications. Euclises Pharmaceuticals leverages groundbreaking inventions from Dr. John Talley, a renowned medicinal chemist known for his development of several approved drugs, including Celebrex. The company's research is centered on compounds that promise enhanced efficacy and safety, positioning Euclises as a significant player in the pharmaceutical industry. It operates out of the BioGenerator Accelerator Labs, fostering a collaborative environment for its innovative pursuits.

Confluence Life Sciences, Inc. is a drug discovery company based in Saint Louis, Missouri, specializing in the design and development of mechanistically novel kinase inhibitors for human and animal health care. Founded in 2010, the company utilizes its KINect technology platform to identify and develop new drugs targeting key enzymes involved in cancer growth, survival, and metastasis, as well as in chronic inflammatory diseases. Confluence Life Sciences distinguishes itself by focusing on novel binding sites and previously undrugged kinases, addressing challenges that other programs have overlooked. The company is supported by a team of experts with extensive pharmaceutical experience in kinase inhibitor discovery and development, enabling it to pursue innovative strategies and targets. Confluence Life Sciences aims to establish scientific and business collaborations to enhance its program pipeline, which follows a cycle of discovery, development, and partnership to meet unmet medical needs.

GeneriCo, LLC is a pharmaceutical company that specializes in the development and marketing of generic medications. Founded in 2013 and headquartered in Saint Louis, Missouri, with additional offices in Bengaluru, India; Italy; and South Korea, GeneriCo focuses on foundational medicines across various therapeutic areas, including cardiovascular health, pain management, central nervous system disorders, oncology, and aging-related conditions. The company distinguishes itself by targeting niche generic pharmaceuticals that have been overlooked by larger competitors, particularly those that involve complex formulations and innovative drug delivery technologies. This strategic focus allows GeneriCo to address specific market needs that are often neglected by mid-sized and large generic companies. GeneriCo serves a global customer base, providing essential medications that contribute to improved health outcomes.

Founded in 2007, Neurolutions develops non-invasive brain-computer interface devices aimed at restoring functionality to individuals disabled by neurological injuries. Their technology uses electroencephalography (EEG) electrodes to interpret intended muscle movements, facilitating rehabilitation and maintaining range of motion.

SanusEO, LLC is a St. Louis-based company that specializes in developing a mobile patient engagement platform (PEP) designed to enhance communication and care between patients and healthcare providers. Founded in 2012, the platform employs data analytics to deliver daily alerts and real-time participant data to care teams, facilitating timely interventions for chronic disease management. SanusEO offers targeted programs such as transition care for patients recently discharged from hospitals and bootcamps for newly diagnosed or at-risk individuals. The platform promotes behavior modification in key health areas, including medication adherence, vital monitoring, diet, and physical activity, with capabilities for multi-language support. By streamlining engagement and intervention processes, SanusEO aims to improve patient outcomes while reducing healthcare costs.

CoverCress Inc. specializes in developing and commercializing field pennycress as a sustainable oilseed crop for industrial oils and livestock feed. Founded in 2013, the company is headquartered in Saint Louis, Missouri.

Euclises Pharmaceuticals, Inc. is a biopharmaceutical company focused on researching, developing, and commercializing innovative medicines for inflammation and oncology. Founded in 2011 and headquartered in Saint Louis, Missouri, the company aims to create novel pain and cancer treatments that demonstrate superior safety profiles compared to existing medications. Euclises Pharmaceuticals leverages groundbreaking inventions from Dr. John Talley, a renowned medicinal chemist known for his development of several approved drugs, including Celebrex. The company's research is centered on compounds that promise enhanced efficacy and safety, positioning Euclises as a significant player in the pharmaceutical industry. It operates out of the BioGenerator Accelerator Labs, fostering a collaborative environment for its innovative pursuits.

RnAgri is a biotechnology company based in St Louis, Missouri, founded in 2011. The company specializes in developing innovative technology for producing ribonucleic acid (RNA). RnAgri's technology tackles challenges associated with mass-producing exogenous RNAi-based products through large-scale fermentation processes. This enables farmers to enhance and safeguard their crops and cattle by providing cost-efficient RNA production solutions.

SynerZ Medical, Inc. develops medical device for the treatment of obesity and type 2 diabetes. The company was incorporated in 2013 and is based in St. Louis, Missouri.

ImmunoPhotonics, Inc. is a biotechnology company focused on developing innovative immunotherapy-based treatments for cancer, specifically targeting metastatic solid tumors. Founded in 2008 and headquartered in Columbia, Missouri, the company has created a proprietary drug product that functions as a minimally invasive autologous cancer vaccine. This treatment involves the intratumoral injection of a carbohydrate polymer following tumor ablation, which harnesses the immune system's response to tumor-associated neoantigens released during the process. By doing so, ImmunoPhotonics aims to generate a systemic anti-tumor immune response, facilitating the treatment of late-stage metastatic cancers. The company has established a strategic partnership with Veterinary Cancer Therapeutics, LLC, enhancing its potential for clinical application.

Kypha Inc. is a life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, the company offers the COMP ACT System, which enhances the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. Through its innovative platform, Kypha provides rapid and accurate assessments of inflammation levels, enabling healthcare professionals to make timely and informed clinical decisions. The company's approach facilitates testing across diverse settings, from home health care to clinical laboratories, ultimately aiming to improve patient outcomes by optimizing treatment strategies based on real-time immune insights. Since its incorporation in 2009, Kypha has attracted significant funding and built a strong network of scientific and clinical expertise to support its mission.

MedSocket is a company that specializes in clinical decision support systems aimed at enhancing the efficiency and quality of patient care. It offers two patented technologies: the 1-Click Decision Support (1-CDS) system and a medical search engine called 1-Search. Designed by clinicians for clinicians, these tools provide rapid access to evidence-based information at the point of care, addressing the urgent information needs of healthcare providers. Both technologies have been successfully piloted at the University of Missouri Health System, demonstrating their potential to improve healthcare decisions, reduce errors, and ultimately enhance patient outcomes. MedSocket was founded by Dr. Karl Kochendorfer, who recognized the challenges healthcare providers faced in accessing timely information, and was later joined by Matt Botkin and Jayne Williams to bring together expertise in business and information science. The company aims to alleviate the burden on clinicians by streamlining information retrieval and decision-making processes in healthcare settings.

Euclises Pharmaceuticals, Inc. is a biopharmaceutical company focused on researching, developing, and commercializing innovative medicines for inflammation and oncology. Founded in 2011 and headquartered in Saint Louis, Missouri, the company aims to create novel pain and cancer treatments that demonstrate superior safety profiles compared to existing medications. Euclises Pharmaceuticals leverages groundbreaking inventions from Dr. John Talley, a renowned medicinal chemist known for his development of several approved drugs, including Celebrex. The company's research is centered on compounds that promise enhanced efficacy and safety, positioning Euclises as a significant player in the pharmaceutical industry. It operates out of the BioGenerator Accelerator Labs, fostering a collaborative environment for its innovative pursuits.

ImmunoPhotonics, Inc. is a biotechnology company focused on developing innovative immunotherapy-based treatments for cancer, specifically targeting metastatic solid tumors. Founded in 2008 and headquartered in Columbia, Missouri, the company has created a proprietary drug product that functions as a minimally invasive autologous cancer vaccine. This treatment involves the intratumoral injection of a carbohydrate polymer following tumor ablation, which harnesses the immune system's response to tumor-associated neoantigens released during the process. By doing so, ImmunoPhotonics aims to generate a systemic anti-tumor immune response, facilitating the treatment of late-stage metastatic cancers. The company has established a strategic partnership with Veterinary Cancer Therapeutics, LLC, enhancing its potential for clinical application.

Tansna Therapeutics, Inc. is a drug discovery and development company focused on creating innovative oral medications for the treatment of epilepsy and other central nervous system disorders. Established in 2010 and headquartered in St. Louis, Missouri, the company is dedicated to developing novel therapies aimed at improving the lives of patients suffering from debilitating conditions. Its main product in development is an oral anticonvulsant agent designed to effectively reduce seizure frequency in individuals with epilepsy, providing healthcare professionals with enhanced treatment options for their patients.

GeneriCo, LLC is a pharmaceutical company that specializes in the development and marketing of generic medications. Founded in 2013 and headquartered in Saint Louis, Missouri, with additional offices in Bengaluru, India; Italy; and South Korea, GeneriCo focuses on foundational medicines across various therapeutic areas, including cardiovascular health, pain management, central nervous system disorders, oncology, and aging-related conditions. The company distinguishes itself by targeting niche generic pharmaceuticals that have been overlooked by larger competitors, particularly those that involve complex formulations and innovative drug delivery technologies. This strategic focus allows GeneriCo to address specific market needs that are often neglected by mid-sized and large generic companies. GeneriCo serves a global customer base, providing essential medications that contribute to improved health outcomes.

Adarza BioSystems is an early-stage medical diagnostics company based in St. Louis, Missouri, that specializes in developing a rapid and label-free biological assay platform for clinical and point-of-care samples. Founded in 2008, the company utilizes its innovative arrayed imaging reflectometry technology to enable the simultaneous detection of hundreds of analytes from a single drop of fluid. This platform allows healthcare professionals to conduct sophisticated tests in a matter of minutes, ensuring high sensitivity and specificity in the detection of multiplexed proteins. Adarza BioSystems aims to enhance diagnostic capabilities, improving patient outcomes through quicker and more accurate testing.

MediBeacon is an optical diagnostics company developing real-time organ function monitoring solutions. Its portfolio focuses on fluorescent tracer-agent systems that enable continuous assessment of kidney function, including the NIC-Kidney device for monitoring glomerular filtration rate in preclinical settings and a renal function system that pairs an optical skin sensor with a proprietary light-activated agent to provide continuous real-time kidney monitoring in clinical environments. The company also maintains a pipeline of light-activated agents for physiological monitoring, surgical guidance and imaging. By commercializing biocompatible optical agents, MediBeacon aims to support critical care and surgical decision-making, enhancing dosing accuracy and patient outcomes in ICUs and operating suites. The technology supports monitoring of kidney and other vital organ functions, helping clinicians intervene in a timely manner.

Tansna Therapeutics, Inc. is a drug discovery and development company focused on creating innovative oral medications for the treatment of epilepsy and other central nervous system disorders. Established in 2010 and headquartered in St. Louis, Missouri, the company is dedicated to developing novel therapies aimed at improving the lives of patients suffering from debilitating conditions. Its main product in development is an oral anticonvulsant agent designed to effectively reduce seizure frequency in individuals with epilepsy, providing healthcare professionals with enhanced treatment options for their patients.

Confluence Life Sciences, Inc. is a drug discovery company based in Saint Louis, Missouri, specializing in the design and development of mechanistically novel kinase inhibitors for human and animal health care. Founded in 2010, the company utilizes its KINect technology platform to identify and develop new drugs targeting key enzymes involved in cancer growth, survival, and metastasis, as well as in chronic inflammatory diseases. Confluence Life Sciences distinguishes itself by focusing on novel binding sites and previously undrugged kinases, addressing challenges that other programs have overlooked. The company is supported by a team of experts with extensive pharmaceutical experience in kinase inhibitor discovery and development, enabling it to pursue innovative strategies and targets. Confluence Life Sciences aims to establish scientific and business collaborations to enhance its program pipeline, which follows a cycle of discovery, development, and partnership to meet unmet medical needs.

Euphrates Vascular is a medical technology company based in St. Louis, Missouri, that focuses on innovative solutions for the treatment of stroke, heart disease, and other conditions. The company has developed a proprietary magnetically-enhanced diffusion (MED) system that utilizes magnet-based technology to dissolve blood clots more rapidly than existing treatment options. This system aims to improve the efficacy of FDA-approved clot-busting medications, potentially reducing mortality rates associated with stroke and cardiovascular diseases. In addition to the MED system, Euphrates Vascular offers MED MicroBeads, which are designed to deliver therapeutic agents directly to clots during thrombolysis therapy, and a touch screen-operated MED Workstation. Founded by physicists with extensive experience in medical technology, the company continues to advance its pioneering approaches in the healthcare sector, attracting interest from investors and media alike.

Kypha Inc. is a life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, the company offers the COMP ACT System, which enhances the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. Through its innovative platform, Kypha provides rapid and accurate assessments of inflammation levels, enabling healthcare professionals to make timely and informed clinical decisions. The company's approach facilitates testing across diverse settings, from home health care to clinical laboratories, ultimately aiming to improve patient outcomes by optimizing treatment strategies based on real-time immune insights. Since its incorporation in 2009, Kypha has attracted significant funding and built a strong network of scientific and clinical expertise to support its mission.

RnAgri is a biotechnology company based in St Louis, Missouri, founded in 2011. The company specializes in developing innovative technology for producing ribonucleic acid (RNA). RnAgri's technology tackles challenges associated with mass-producing exogenous RNAi-based products through large-scale fermentation processes. This enables farmers to enhance and safeguard their crops and cattle by providing cost-efficient RNA production solutions.

ARTA Bioscience, Inc is developing new therapeutics for prostate cancer and inflammatory diseases. Current treatments for prostate cancer are insufficient and the disease is the second leading cause of cancer deaths among American men. ARTA's technology involves an entirely different approach to combating disease compared to traditional treatments. In addition to prostate cancer, the company's technologies may be used to target other important proteins in the nuclear receptor class. The company has established operations at the BioGenerator Accelerator Labs. ARTA's technology was developed by Dr. Marc Diamond at Washington University.

Mobius Therapeutics develops sterile injectable pharmaceutical products for ophthalmic applications. Its flagship product is Mitosol, a closed-system transfer device containing mitomycin for solution, used by ophthalmologists to prevent scarring during glaucoma, refractive, and corneal surgeries.

Euphrates Vascular is a medical technology company based in St. Louis, Missouri, that focuses on innovative solutions for the treatment of stroke, heart disease, and other conditions. The company has developed a proprietary magnetically-enhanced diffusion (MED) system that utilizes magnet-based technology to dissolve blood clots more rapidly than existing treatment options. This system aims to improve the efficacy of FDA-approved clot-busting medications, potentially reducing mortality rates associated with stroke and cardiovascular diseases. In addition to the MED system, Euphrates Vascular offers MED MicroBeads, which are designed to deliver therapeutic agents directly to clots during thrombolysis therapy, and a touch screen-operated MED Workstation. Founded by physicists with extensive experience in medical technology, the company continues to advance its pioneering approaches in the healthcare sector, attracting interest from investors and media alike.

PixelEXX Systems Inc. is a company based in Saint Louis, Missouri, that specializes in developing innovative imaging devices aimed at cancer diagnosis. Founded in 2008, the company focuses on creating prototype imaging technologies that utilize advanced nanoarrays to capture images of molecular signals linked to cellular activity. Their proprietary image sensors incorporate novel nano resonant photodiodes, which enhance sensitivity and allow for the capture of wavelength and polarization information without relying on microlenses, filters, or separate metasurfaces. This unique approach enables clients to optimize imaging and sensing capabilities while reducing size, weight, and power consumption of the devices.

APT Therapeutics is a biotechnology company based in St. Louis, Missouri. It develops antiplatelet therapies for acute myocardial infarction, stroke, and transplantation-related complications. The company uses protein engineering, protein informatics, and cheminformatics software to design base therapeutics and molecular drugs for thrombotic diseases, with the aim of minimizing tissue damage during heart events.